Cell Therapeutics News

Rainbow Biosciences, the biotechnology subsidiary of Rainbow Coral Corp. , announced today that the company is currently discussing a potential joint venture with emerging biotech innovator Amarantus BioSciences .

Cell Therapeutics said its cancer drug pixantrone has been approved by the European Commission for treating late-stage, aggressive B-cell non-Hodgkin lymphomas that haven't responded to other therapies.

Boston Scientific's current acquisition, Cameron Health, reports that its implantable heart defibrillator was safe and effective in a trial involving 330 patients.

Cell Therapeutics' PixuvriA Approved in European Union as Monotherapy to Treat Adult Patients with Multiply Relapsed or Refractory Aggressive Non-Hodgkin B-Cell Lymphomas SEATTLE, May 10, 2012 /PRNewswire/ -- Cell Therapeutics, Inc.

The iShares NASDAQ Biotechnology Index is up nearly 20 percent year-to-date. The passage of the America Invents Act will look to benefit the Biotechnology Industry going forward "by enhancing patent quality and the efficiency, objectivity, predictability and transparency of the U.S. patent system." BIO President and CEO Jim Greenwood stated in a ... (more)

NOKOMIS, Fla. -- -- Rainbow BioSciences, LLC, the biotech subsidiary of Rainbow Coral Corp.

NOKOMIS, Fla. & SUNNYVALE, Calif. -- -- Rainbow BioSciences, a subsidiary of Rainbow Coral Corp has executed a Letter Of Intent to advance Amarantus BioSciences, Inc.'s Parkinson's disease program, comprised of an early detection diagnostic blood test and a disease-modifying protein drug candidate.

One biotech stock that is currently on its way back up is Dendreon . Dendreon is a growing player in the biotech industry with a 1.5 current ratio reported, although this number inspires less confidence than that of other biotech companies such as Jazz Pharmaceuticals , and Cell Therapeutics , with current ratios of 4.2 and 3.1, respectively.

Watson Pharmaceuticals of the US acquired privately held Actavis Group at a price of about $5.6 billion upfront, plus earn-out provisions based on 2012 results .